Salvage-targeted kidney cancer therapy in patients progressing on high-dose interleukin-2 immunotherapy: The UCLA experience

Cancer Journal (United States)

Volumn 19, Issue 3, 2013, Pages 189-196

  Birkhäuser, Frédéric D ^a,b   Pantuck, Allan J ^a   Rampersaud, Edward N ^a   Wang, Xiaoyan ^c   Kroeger, Nils ^a   Pouliot, Frédéric ^a   Zomorodian, Nazy ^a   Riss, Joseph ^a   Li, Gang ^c   Kabbinavar, Fairooz F ^a   Belldegrun, Arie S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Immunotherapy; Interleukin 2; Molecular targeted therapy; Renal cell carcinoma; Salvage therapy

Indexed keywords

BEVACIZUMAB; EVEROLIMUS; INTERLEUKIN 2; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADULT; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SPECIFIC SURVIVAL; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; CYTOREDUCTIVE SURGERY; DISEASE SPECIFIC SURVIVAL; DRUG MEGADOSE; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; NEPHRECTOMY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84880123722     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318292e8a4     Document Type: Article

References (20)

1. Rosenberg SA. Cancer immunotherapy comes of age. Nat Clin Pract Oncol. 2005;2:115.
2. Belldegrun AS, Klatte T, Shuch B, et al. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies. Cancer. 2008;113:2457-2463.
3. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688-696.
4. Upton MP, Parker RA, Youmans A, et al. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother. 2005;28:488-495.
5. Leibovich BC, Han KR, Bui MH, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;98:2566-2575.
6. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5: 649-655.
7. Klatte T, Pantuck AJ, Kleid MD, et al. Understanding the natural biology of kidney cancer: implications for targeted cancer therapy. Rev Urol. 2007;9:47-56.
8. Sobin LH, Wittekind CH, eds. International Union Against Cancer (UICC). TNM Classification of Malignant Tumours. 6th ed. New York, NY: Wiley-Liss; 2002.
9. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6: 655-663.
10. Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002;20: 4559-4566.
11. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003;9: 802-811.
12. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association. 1958;53: 457-481.
14. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. 1966;50:163-170.
15. Cox DR. Regression models and life-tables. Journal of the Royal Statistical Society, Series B (Methodological). 1972;34:187-220.
16. Haddad H, Rini BI. Current treatment considerations in metastatic renal cell carcinoma. Curr Treat Options Oncol. 2012;13:212-229.
17. Patard JJ, Pignot G, Escudier B, et al. ICUD-EAU international consultation on kidney cancer 2010: treatment of metastatic disease. Eur Urol. 2011;60:684-690.
18. Hutson TE, Bukowski RM, Cowey CL, et al. Sequential use of targeted agents in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol. 2011;77:48-62.
19. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103-2111.
20. Cho DC, Puzanov I, Regan MM, et al. Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma. J Immunother. 2009;32:181-185.